바이러스 벡터 및 플라스미드 DNA 제조 시장 규모, 점유율 및 동향 분석 보고서 : 벡터 유형별, 워크플로우별, 용도별, 최종 용도별, 질병별, 지역별, 부문별 예측(2024-2030년)

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends:

The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights:

• Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
• Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
• Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
• Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
• In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
• North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Vector type
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. End-use
  • 1.2.5. Disease
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
    • 3.2.1.2. Technological Advancements in Manufacturing Vectors
    • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
• 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

• 4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
• 4.2. Adeno-associated virus (AAV)
  • 4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.3. Lentivirus
  • 4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.4. Adenovirus
  • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.5. Retrovirus
  • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.6. Plasmids
  • 4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

• 5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
• 5.2. Upstream Manufacturing
  • 5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.2.2. Vector Amplification & Expansion
    • 5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.2.3. Vector Recovery/Harvesting
    • 5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 5.3. Downstream Manufacturing
  • 5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3.2. Purification
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.3.3. Fill Finish diagnostic instruments
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

• 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
• 6.2. Gene Therapy
  • 6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.3. Cell Therapy
  • 6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.4. Vaccinology
  • 6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 6.5. Research Applications
  • 6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis

• 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
• 7.2. Pharmaceutical and Biopharmaceutical Companies
  • 7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 7.3. Research Institutes
  • 7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

• 8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
• 8.2. Cancer
  • 8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.3. Genetic Disorders
  • 8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.4. Infectious Diseases
  • 8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 8.5. Other
  • 8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Regulatory framework
    • 9.2.2.3. Competitive scenario
    • 9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.2.5. Target disease prevalence
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Regulatory framework
    • 9.2.3.3. Competitive scenario
    • 9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.2.3.5. Target disease prevalence
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.2.5. Target disease prevalence
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.3.5. Target disease prevalence
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive scenario
    • 9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.4.5. Target disease prevalence
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Regulatory framework
    • 9.3.5.3. Competitive scenario
    • 9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.5.5. Target disease prevalence
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Regulatory framework
    • 9.3.6.3. Competitive scenario
    • 9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.6.5. Target disease prevalence
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Regulatory framework
    • 9.3.7.3. Competitive scenario
    • 9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.7.5. Target disease prevalence
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Regulatory framework
    • 9.3.8.3. Competitive scenario
    • 9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.8.5. Target disease prevalence
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Regulatory framework
    • 9.3.9.3. Competitive scenario
    • 9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.3.9.5. Target disease prevalence
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.2.5. Target disease prevalence
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.3.5. Target disease prevalence
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.4.5. Target disease prevalence
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.5.5. Target disease prevalence
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.6.5. Target disease prevalence
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.4.7.5. Target disease prevalence
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.2.5. Target disease prevalence
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.3.5. Target disease prevalence
  • 9.5.4. Argentina
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.5.4.5. Target disease prevalence
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.2.5. Target disease prevalence
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.3.5. Target disease prevalence
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.4.5. Target disease prevalence
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
    • 9.6.5.5. Target disease prevalence

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Lonza
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. FUJIFILM Diosynth Biotechnologies
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Cobra Biologics
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Catalent Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Wuxi Biologics
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Takara Bio Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Waisman Biomanufacturing
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Genezen laboratories
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Batavia Biosciences
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Miltenyi Biotec GmbH
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. SIRION Biotech GmbH
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Virovek Incorporation
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. BioNTech IMFS GmbH
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product benchmarking
    • 10.4.15.4. Strategic initiatives
  • 10.4.16. Audentes Therapeutics
    • 10.4.16.1. Company overview
    • 10.4.16.2. Financial performance
    • 10.4.16.3. Product benchmarking
    • 10.4.16.4. Strategic initiatives
  • 10.4.17. BioMarin Pharmaceutical
    • 10.4.17.1. Company overview
    • 10.4.17.2. Financial performance
    • 10.4.17.3. Product benchmarking
    • 10.4.17.4. Strategic initiatives
  • 10.4.18. RegenxBio, Inc.
    • 10.4.18.1. Company overview
    • 10.4.18.2. Financial performance
    • 10.4.18.3. Product benchmarking
    • 10.4.18.4. Strategic initiatives